Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-02-24

    Virtual Booth

    Contact Supplier

    Menu

    Lenvatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,521Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck, Eisai combo misses survival goal in GI cancer trial
    Merck, Eisai combo misses survival goal in GI cancer trial

    25 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-eisai-star-crossed-keytruda-lenvima-combo-misses-survival-goal-gi-cancer-trial

    FIERCE PHARMA
    25 Jan 2025
    Share Share
    KEYTRUDA Plus LENVIMA With TACE Improves PFS In Liver Cancer
    KEYTRUDA Plus LENVIMA With TACE Improves PFS In Liver Cancer

    14 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240914167509/en

    BUSINESSWIRE
    14 Sep 2024
    Share Share
    Medivir To Present Fostrox + Lenvima Data At ESMO And Host Webcast
    Medivir To Present Fostrox + Lenvima Data At ESMO And Host Webcast

    12 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-to-present-mature-clinical-data-for-fostrox--lenvima-at-esmo-conference-and-to-host-a-webcast-on-september-16-302246468.html

    PR NEWSWIRE
    12 Sep 2024
    Share Share
    Eisai To Present E7386 At ESMO Annual Meeting
    Eisai To Present E7386 At ESMO Annual Meeting

    08 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-to-present-e7386-co-created-by-prism-biolab-and-eisai-at-the-esmo-european-society-for-medical-oncology-annual-meeting-302241213.html

    PR NEWSWIRE
    08 Sep 2024
    Share Share
    Medivir To Present Fostrox + Lenvima HCC Data At ESMO Conference
    Medivir To Present Fostrox + Lenvima HCC Data At ESMO Conference

    18 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-to-present-updated-clinical-data-for-fostrox--lenvima-in-hcc-at-esmo-conference-in-september-302200401.html

    PR NEWSWIRE
    18 Jul 2024
    Share Share
    New Analysis From Phase 3 REFLECT Trial On LENVIMA At ESMO GI 2024
    New Analysis From Phase 3 REFLECT Trial On LENVIMA At ESMO GI 2024

    27 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-post-hoc-analysis-from-phase-3-reflect-trial-presented-at-esmo-gi-2024-explores-efficacy-outcomes-with-lenvima-lenvatinib-based-on-depth-of-tumor-response-in-unresectable-hepatocellular-carcinoma-302184539.html

    PR NEWSWIRE
    27 Jun 2024
    Share Share